{"organizations": [], "uuid": "6603fe0ac362e5eade767540216e9b16ae9ebd6b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pfizer-receives-positive-chmp-opin/brief-pfizer-receives-positive-chmp-opinion-for-two-hematology-medicines-idUSFWN1QD16B", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer Receives Positive CHMP Opinion For Two Hematology Medicines", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T16:12:00.000+02:00", "replies_count": 0, "uuid": "6603fe0ac362e5eade767540216e9b16ae9ebd6b"}, "author": "", "url": "https://www.reuters.com/article/brief-pfizer-receives-positive-chmp-opin/brief-pfizer-receives-positive-chmp-opinion-for-two-hematology-medicines-idUSFWN1QD16B", "ord_in_thread": 0, "title": "BRIEF-Pfizer Receives Positive CHMP Opinion For Two Hematology Medicines", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "two hematology medicines", "sentiment": "negative"}, {"name": "chmp opinion for two hematology medici", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 15 PM / Updated 9 minutes ago BRIEF-Pfizer Receives Positive CHMP Opinion For Two Hematology Medicines Reuters Staff Feb 23 (Reuters) - Pfizer Inc: * PFIZER RECEIVES POSITIVE CHMP OPINION FOR TWO HEMATOLOGY MEDICINES, MYLOTARG™ AND BOSULIF® * PFIZER INC - CHMP OF EMA HAS ADOPTED POSITIVE OPINIONS RECOMMENDING THAT MYLOTARG, BOSULIF BE GRANTED MARKETING AUTHORIZATIONS IN EU Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-23T16:12:00.000+02:00", "crawled": "2018-02-23T16:33:30.005+02:00", "highlightTitle": ""}